SCHEMBL6717026

SCHEMBL6717026

NC(C(=O)Nc1ccc([N+](=O)[O-])cc1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
NPC1 O15118 3/20 0.57
RAB9A P51151 2/20 0.57
MITF O75030 1/20 0.57
POLB P06746 1/20 0.57
MAPT P10636 3/20 0.51
GAA P10253 2/20 0.50
ALOX12 P18054 2/20 0.50
FNTA P49354 1/20 0.50
FNTB P49356 1/20 0.50
HPGD P15428 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 2/20 0.49
MGLL Q99685 1/20 0.49
ROCK2 O75116 1/20 0.49
ROCK1 Q13464 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29206349 0.84 MEN1 (0.59) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL29206352 0.84 MEN1 (0.59) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL4982071 0.82 POLB (0.66) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL19074543 0.82 POLB (0.66) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL23611205 0.81 ROCK2 (0.56) MEN1KMT2APOLBMAPTHPGD
SCHEMBL23611208 0.81 ROCK2 (0.56) MEN1KMT2APOLBMAPTHPGD
Hydrochloric Acid SCHEMBL8010089 0.81 POLB (0.63) MEN1KMT2ANPC1RAB9APOLB
Hydrochloric Acid SCHEMBL8010083 0.81 POLB (0.63) MEN1KMT2ANPC1RAB9APOLB
SCHEMBL6717493 0.80 MEN1 (0.55) MEN1KMT2ANPC1RAB9AMITF
SCHEMBL8337821 0.80 MEN1 (0.55) MEN1KMT2ANPC1RAB9AMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 MEN1 2933/4885KMT2A 2020/4885NPC1 120/4885
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 MEN1 2822/4885KMT2A 1656/4885NPC1 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.